DK2084151T3 - Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme - Google Patents

Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme

Info

Publication number
DK2084151T3
DK2084151T3 DK07818948.7T DK07818948T DK2084151T3 DK 2084151 T3 DK2084151 T3 DK 2084151T3 DK 07818948 T DK07818948 T DK 07818948T DK 2084151 T3 DK2084151 T3 DK 2084151T3
Authority
DK
Denmark
Prior art keywords
cardiovascular
treatment
hematological disorders
dihydropyrazolones
substituted
Prior art date
Application number
DK07818948.7T
Other languages
English (en)
Inventor
Ingo Flamme
Felix Oehme
Jens-Kerim Ergueden
Friederike Stoll
Joachim Schuhmacher
Hanno Wild
Peter Kolkhof
Joerg Keldenich
Metin Akbaba
Mario Jeske
Kai Thede
Hartmut Beck
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Application granted granted Critical
Publication of DK2084151T3 publication Critical patent/DK2084151T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
DK07818948.7T 2006-10-26 2007-10-12 Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme DK2084151T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006050516A DE102006050516A1 (de) 2006-10-26 2006-10-26 Substituierte Dihydropyrazolone und ihre Verwendung
PCT/EP2007/008877 WO2008067871A1 (de) 2006-10-26 2007-10-12 Substituierte dihydropyrazolone zur behandlung kardiovaskulärer und hämatologischer erkrankungen

Publications (1)

Publication Number Publication Date
DK2084151T3 true DK2084151T3 (da) 2013-09-02

Family

ID=38734870

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07818948.7T DK2084151T3 (da) 2006-10-26 2007-10-12 Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme
DK12188156.9T DK2546253T3 (da) 2006-10-26 2007-10-12 Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12188156.9T DK2546253T3 (da) 2006-10-26 2007-10-12 Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme

Country Status (41)

Country Link
US (5) US8389520B2 (da)
EP (3) EP2546253B1 (da)
JP (2) JP5247712B2 (da)
KR (1) KR101455879B1 (da)
CN (2) CN101631785B (da)
AR (1) AR063392A1 (da)
AU (1) AU2007328052B2 (da)
BR (1) BRPI0717367B8 (da)
CA (1) CA2667382C (da)
CO (1) CO6170359A2 (da)
CR (2) CR10750A (da)
CU (2) CU23743B7 (da)
CY (1) CY1114272T1 (da)
DE (1) DE102006050516A1 (da)
DK (2) DK2084151T3 (da)
ES (3) ES2421454T3 (da)
GT (1) GT200900095A (da)
HK (2) HK1140478A1 (da)
HN (1) HN2009000784A (da)
HR (2) HRP20130779T1 (da)
IL (2) IL198289A (da)
MA (1) MA30914B1 (da)
MX (1) MX2009004324A (da)
MY (1) MY169564A (da)
NO (1) NO343308B1 (da)
NZ (2) NZ596583A (da)
PE (3) PE20080895A1 (da)
PH (1) PH12013500578B1 (da)
PL (2) PL2084151T3 (da)
PT (2) PT2546253E (da)
RS (1) RS52924B (da)
RU (2) RU2469031C2 (da)
SG (1) SG176421A1 (da)
SI (1) SI2084151T1 (da)
SV (1) SV2009003236A (da)
TN (1) TN2009000132A1 (da)
TW (3) TWI561237B (da)
UA (1) UA98125C2 (da)
UY (1) UY30663A1 (da)
WO (1) WO2008067871A1 (da)
ZA (1) ZA200902705B (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
EP2294066B9 (en) 2008-04-28 2015-03-11 Janssen Pharmaceutica, N.V. Benzoimidazoles as prolyl hydroxylase inhibitors
FR2940651B1 (fr) * 2008-12-29 2013-05-03 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique comme activateurs de hif
JP5865704B2 (ja) 2008-12-29 2016-02-17 サノフイ ２−ピリジン−２−イル−ピラゾール−３（２ｈ）−オンの誘導体、この調製および治療的使用
EA019591B1 (ru) * 2008-12-29 2014-04-30 Санофи Производные 2-пиридин-2-ил-пиразол-3(2h)-она, их получение и применение в терапии в качестве активаторов hif
FR2949466A1 (fr) * 2009-08-28 2011-03-04 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif
IT1393337B1 (it) 2009-03-06 2012-04-20 Italiana Sint Spa Sintesi di (4as, 7as)-ottaidro-1h-pirrolo[3,4-b]piridina
DE102010044131A1 (de) * 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
ES2574262T3 (es) 2011-10-25 2016-06-16 Janssen Pharmaceutica, N.V. Formulaciones de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
EP2628722A1 (en) * 2012-02-16 2013-08-21 Bayer CropScience AG CF3O-containing enaminoketones and their utilization for the preparation of CF3O-containing pyrazoles
CN104321318A (zh) 2012-03-30 2015-01-28 第一三共株式会社 4-烷酰基氨基-3-吡唑啉酮衍生物
PL2847183T3 (pl) * 2012-05-08 2017-11-30 Bayer Pharma Aktiengesellschaft Sposób wytwarzania związków triazolowych
CN104334565A (zh) 2012-05-29 2015-02-04 莫门蒂夫性能材料有限责任公司 异氰酸基硅烷的制备
HUE038220T2 (hu) 2013-03-29 2018-10-29 Takeda Pharmaceuticals Co 6-(5-Hidroxi-lH-pirazol-1-il)nikotinamid származékok és PHD inhibitorként való alkalmazásuk
CU24515B1 (es) 2013-10-17 2021-05-12 Bayer Pharma AG Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio
WO2016034108A1 (zh) 2014-09-02 2016-03-10 广东东阳光药业有限公司 喹啉酮类化合物及其应用
CN107778262A (zh) * 2016-08-24 2018-03-09 尹玉新 1,5‑双取代四氮唑类化合物及其制备方法和应用
CN109694380B (zh) * 2017-10-23 2022-09-27 中国医药研究开发中心有限公司 二氢吡唑啉酮类化合物及其制备方法和医药用途
CN111825690B (zh) * 2019-04-17 2022-09-27 中国医药研究开发中心有限公司 一种phd抑制剂的新晶型及其制备方法
US11579118B2 (en) 2019-06-03 2023-02-14 Tdw Delaware, Inc. Single point contact triaxial sensor head for an inline inspection tool
US10702525B1 (en) 2019-09-04 2020-07-07 United Arab Emirates University Pyrimidine derivatives as anti-diabetic agents
WO2021163727A1 (en) * 2020-02-11 2021-08-19 AcuraStem Incorporated Pikfyve kinase inhibitors
BR112022016400A2 (pt) 2020-02-18 2022-10-25 Bayer Ag Compostos inovadores de heteroaril-triazol como pesticidas
CN115605467A (zh) * 2020-03-20 2023-01-13 阿克比治疗有限公司（Us） Phd抑制剂化合物、组合物和其用途
EP3888684A1 (en) 2020-03-31 2021-10-06 Bayer Animal Health GmbH Composition having improved voluntary acceptance
TW202200134A (zh) 2020-04-20 2022-01-01 美商阿克比治療有限公司 治療病毒感染、器官損傷及相關症狀之方法
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
CN116120340B (zh) * 2021-11-15 2023-10-31 艾立康药业股份有限公司 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE424016C (de) 1923-05-20 1926-01-14 Allg Vergasungs Ges M B H Fa Schachtofen mit Schwelaufsatz zur Vergasung und Verschwelung bituminoeser Stoffe
FR1519069A (fr) 1966-04-13 1968-03-29 Geigy Ag J R Dérivés du sulfanilamide et leur préparation
GR63123B (en) 1975-12-11 1979-09-11 Lilly Co Eli Preparation process of novel 1,4-diphenyl-3-pyrazolin-5-ones
US4075003A (en) 1975-12-11 1978-02-21 Eli Lilly And Company Novel herbicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones
PL103509B1 (pl) 1976-09-20 1979-06-30 Lilly Co Eli Srodek chwastobojczy
US4663327A (en) 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (de) * 1984-11-28 1986-05-28 Bayer Ag, 5090 Leverkusen 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
DE3527157A1 (de) 1985-07-30 1987-02-12 Bayer Ag 1-heteroaryl-4-aryl-pyrazol-derivate
DE4204919A1 (de) 1992-02-19 1993-08-26 Bayer Ag Verfahren zur herstellung von 2-chlor-5-alkylaminomethyl-pyridinen
DE4240168A1 (de) 1992-11-30 1994-06-01 Bayer Ag Cumarin-Derivate, Verfahren zu ihrer Herstellung und ihrer Verwendung
FR2725988B1 (fr) 1994-10-24 1997-01-24 Roussel Uclaf Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
JPH10306077A (ja) * 1997-05-07 1998-11-17 Daiichi Rajio Isotope Kenkyusho:Kk ビピラゾール誘導体並びにこれを有効成分とする医薬および試薬
DE19909237A1 (de) 1999-03-03 2000-09-07 Merck Patent Gmbh Pyrazol-3-on-derivate
ES2220753T3 (es) * 2000-03-20 2004-12-16 N-Gene Research Laboratories Inc. Derivados de amidoxina del acido propencarboxilico, procedimiento para su preparacion, y composiciones farmaceuticas que los contienen.
US6878729B2 (en) * 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
CA2446864C (en) 2001-05-16 2011-02-15 Vertex Pharmaceuticals Incorporated Inhibitors of src and other protein kinases
EP1458383B1 (en) 2001-12-18 2007-11-21 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US20040176372A1 (en) 2002-03-01 2004-09-09 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
EP1613311A4 (en) 2003-03-27 2010-04-14 Univ Emory HIF-1 INHIBITORS
US20060194807A1 (en) 2003-04-03 2006-08-31 Cosford Nicholas D P Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
AU2004236690A1 (en) 2003-05-01 2004-11-18 Panacea Pharmaceuticals, Inc. Methods of treating ischemic related conditions
AU2004275694B2 (en) * 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
AT7634U1 (de) 2004-06-29 2005-06-27 Binder Co Ag Detektiervorrichtung und sortiervorrichtung
WO2006088491A2 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
CA2601098C (en) 2005-03-16 2011-07-05 Aventis Pharmaceuticals Inc. Dipyrazoles as central nervous system agents
KR20080000622A (ko) * 2005-04-26 2008-01-02 뉴로서치 에이/에스 신규한 옥사디아졸 유도체 및 이의 의학적 용도
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
DE102010044131A1 (de) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat

Also Published As

Publication number Publication date
CN101631785B (zh) 2013-08-21
US20140031329A1 (en) 2014-01-30
ES2534872T3 (es) 2015-04-29
AU2007328052B2 (en) 2013-11-07
RU2469031C2 (ru) 2012-12-10
ES2621787T3 (es) 2017-07-05
EP2383269A2 (de) 2011-11-02
PT2084151E (pt) 2013-07-18
PT2546253E (pt) 2015-05-07
HRP20130779T1 (hr) 2013-09-30
ZA200902705B (en) 2010-06-30
US8389520B2 (en) 2013-03-05
CY1114272T1 (el) 2016-08-31
PL2084151T3 (pl) 2013-10-31
TW200833330A (en) 2008-08-16
UY30663A1 (es) 2008-05-31
MY169564A (en) 2019-04-22
JP2010507602A (ja) 2010-03-11
US20100305085A1 (en) 2010-12-02
CN103342696A (zh) 2013-10-09
IL221928A (en) 2015-10-29
TWI561237B (en) 2016-12-11
TW201345526A (zh) 2013-11-16
CU20090066A7 (es) 2011-09-21
AR063392A1 (es) 2009-01-28
ES2421454T3 (es) 2013-09-02
PH12013500578A1 (en) 2014-09-08
KR101455879B1 (ko) 2014-11-03
PE20120635A1 (es) 2012-05-20
EP2546253A1 (de) 2013-01-16
UA98125C2 (ru) 2012-04-25
CO6170359A2 (es) 2010-06-18
PL2546253T3 (pl) 2015-08-31
SG176421A1 (en) 2011-12-29
PE20120620A1 (es) 2012-05-27
US20160229858A1 (en) 2016-08-11
RU2012134284A (ru) 2014-02-20
RU2611012C2 (ru) 2017-02-17
MX2009004324A (es) 2009-05-12
US8653111B2 (en) 2014-02-18
US20120121727A1 (en) 2012-05-17
SI2084151T1 (sl) 2013-10-30
WO2008067871A1 (de) 2008-06-12
CR10750A (es) 2009-09-16
EP2084151B1 (de) 2013-05-29
BRPI0717367B8 (pt) 2021-05-25
KR20090074811A (ko) 2009-07-07
EP2383269B1 (de) 2017-01-18
HN2009000784A (es) 2012-02-27
SV2009003236A (es) 2010-01-19
PH12013500578B1 (en) 2014-09-08
TWI437991B (zh) 2014-05-21
MA30914B1 (fr) 2009-11-02
IL198289A0 (en) 2010-02-17
BRPI0717367A2 (pt) 2013-10-22
GT200900095A (es) 2011-10-12
US9168249B2 (en) 2015-10-27
CN101631785A (zh) 2010-01-20
US20150148381A1 (en) 2015-05-28
EP2383269A3 (de) 2012-01-11
DE102006050516A1 (de) 2008-04-30
EP2084151A1 (de) 2009-08-05
HK1140478A1 (en) 2010-10-15
TN2009000132A1 (en) 2010-10-18
IL198289A (en) 2015-03-31
PE20080895A1 (es) 2008-09-05
US8987261B2 (en) 2015-03-24
DK2546253T3 (da) 2015-04-20
HRP20150396T1 (hr) 2015-05-08
CU20110119A7 (es) 2012-01-31
NZ576458A (en) 2011-12-22
NO343308B1 (no) 2019-01-28
CA2667382C (en) 2014-12-23
HK1190153A1 (en) 2014-06-27
EP2546253B1 (de) 2015-01-14
CU23743B7 (es) 2012-01-31
RS52924B (en) 2014-02-28
CN103342696B (zh) 2015-03-11
AU2007328052A1 (en) 2008-06-12
JP5300813B2 (ja) 2013-09-25
RU2009119431A (ru) 2010-12-10
CR20140392A (es) 2014-09-16
CU24056B1 (es) 2014-12-26
BRPI0717367B1 (pt) 2020-09-08
TW201630605A (zh) 2016-09-01
NZ596583A (en) 2013-05-31
NO20091655L (no) 2009-06-26
JP2011006486A (ja) 2011-01-13
CA2667382A1 (en) 2008-06-12
JP5247712B2 (ja) 2013-07-24

Similar Documents

Publication Publication Date Title
DK2084151T3 (da) Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK2124999T3 (da) Activin-actrii antagonister og anvendelser til behandling af anæmi
DK2137537T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK2570467T3 (da) Sammensætninger af tetrafluorpropen og carbonhydrider
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
DK1877232T3 (da) Fremgangsmåde til behandling af træoverflader
DK2155188T3 (da) Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
DK1948176T3 (da) Diarylurinstoffer til behandling af pulmonær hypertension
DK2081669T3 (da) Fremgangsmåde og anordning til fremstilling af granulater
DE602007010795D1 (de) Blattsauger und -häcksler
CY2016017I1 (el) Συνθεση για θεραπεια πνευμονικης υπερτασης
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
DK3121169T3 (da) Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser
DK2101819T3 (da) Fremgangsmåder, sammensætninger og kits til behandling af smerte og pruritis
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK2894165T3 (da) Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
DK2839830T3 (da) Kits og sammensætninger til behandling af lidelser i de nedre urinveje
DK2170360T3 (da) Urtesammensætning til behandling af diabetes og/eller forstyrrelser forbundet dermed
DK1961223T3 (da) Fremgangsmåde til kontrol af tilgang til et kodet indhold
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK2120604T3 (da) Fremgangsmåde til fraktionering af havre, produkter derved opnået, og anvendelser deraf
DK1896077T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af inflammatoriske sygdomme